You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMagnesium salicylate
Accession NumberDB01397
TypeSmall Molecule
GroupsApproved
DescriptionMagnesium salicylate is a common analgesic and non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate muscular pain. It is also used to treat headaches, general back pain, and certain joint pains like arthritis. It is found in a variety of over-the-counter (OTC) medications as an anti-inflammatory, primarily for back-pain relief. Magnesium Salicylate can be an effective OTC alternative to prescription NSAIDs, with both anti-inflamatory and pain-relieving effects. Though the recommended doseage is 1160 mg every six hours, per package directions of the Doan's OTC brand (580 mg magnesium salicylate tetrahydrate, equivalent to 934.4 mg anhydrous magnesium salicylate), effective pain relief is often found with a half dosage, with reduced anti-inflammatory results.
Structure
Thumb
Synonyms
Magnesium salicylate anhydrous
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Back-ese M Tab 325mgtablet325 mgG.T. Fulford Pharmaceuticals1985-12-311998-06-25Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Arthriten Tabletstablet325 mgoralAlva Amco Pharmacal Companies, Inc.2003-05-152006-07-27Canada
Back-ese M Tablets 325 mgtablet325 mgoralDannorth Laboratories Inc.1980-12-312000-07-19Canada
Backache Aidtablet, film coated580 mg/1oralL&R Distributors, Inc.1998-11-07Not applicableUs
Backache Relieftablet, film coated580 mg/1oralRite Aid1998-11-07Not applicableUs
Backache Relieftablet, film coated580 mg/1oralWOONSOCKET PRESCRIPTION CENTER,INCORPORATED1998-11-07Not applicableUs
Backache Relief Extra Strengthtablet580 mg/1oralWALGREEN CO.1998-11-07Not applicableUs
Backache Relief Extra Strengthtablet, film coated580 mg/1oralL.N.K. International, Inc.1998-11-07Not applicableUs
Doan's Backache Pills 325mgtablet325 mgoralNovartis Consumer Health Canada Inc.1988-12-311998-07-08Canada
Doans Extra Strengthtablet580 mg/1oralDucere Pharma LLC2013-05-15Not applicableUs
Extra Strength Backache Reliefcapsule580 mg/1oralFamily Dollar1998-11-07Not applicableUs
Herbogesictablet650 mgoralSeroyal International Inc.1988-12-312009-07-06Canada
Kneerelief Tabletstablet650 mgoralAlva Amco Pharmacal Companies, Inc.2003-05-152006-07-27Canada
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Back ReliefNorth Safety Products LLC
Diurex Water PillsAlva Amco Pharmacal Companies, Inc.
Medique Back Pain OffUnifirst First Aid Corporation
Otis Clapp Back QuellUnifirst First Aid Corporation
Pain Aid BrfZee Medical Inc
Pamprin Cramp Menstrual Pain ReliefChattem, Inc.
Trilisate TabPurdue Pharma
Vica-cetProvision Medical Products
Salts
Name/CASStructureProperties
Magnesium salicylate tetrahydrate
18917-95-8
Thumb
  • InChI Key: CWQGWAKCTBFURY-UHFFFAOYSA-J
  • Monoisotopic Mass: 368.05938842
  • Average Mass: 368.577
DBSALT001864
Categories
UNIIJQ69D454N1
CAS number18917-89-0
WeightAverage: 298.531
Monoisotopic: 298.03277995
Chemical FormulaC14H10MgO6
InChI KeyInChIKey=MQHWFIOJQSCFNM-UHFFFAOYSA-L
InChI
InChI=1S/2C7H6O3.Mg/c2*8-6-4-2-1-3-5(6)7(9)10;/h2*1-4,8H,(H,9,10);/q;;+2/p-2
IUPAC Name
magnesium(2+) ion bis(2-hydroxybenzoate)
SMILES
[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as salicylic acids. These are ortho-hydroxylated benzoic acids.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentSalicylic acids
Alternative Parents
Substituents
  • Salicylic acid
  • Benzoic acid
  • Benzoyl
  • Phenol
  • Vinylogous acid
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Carbonyl group
  • Organic zwitterion
  • Aromatic homomonocyclic compound
Molecular FrameworkNot Available
External DescriptorsNot Available
Pharmacology
IndicationMagnesium salicylate is a common analgesic and non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate muscular pain
PharmacodynamicsNot Available
Mechanism of actionMost NSAIDs act as nonselective inhibitors of the enzyme cyclooxygenase (COX), inhibiting both the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes. COX catalyzes the formation of prostaglandins and thromboxane from arachidonic acid (itself derived from the cellular phospholipid bilayer by phospholipase A2). Prostaglandins act (among other things) as messenger molecules in the process of inflammation.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Magnesium salicylate Action PathwayDrug actionSMP00698
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5741
Blood Brain Barrier+0.829
Caco-2 permeable+0.5941
P-glycoprotein substrateNon-substrate0.6758
P-glycoprotein inhibitor INon-inhibitor0.9704
P-glycoprotein inhibitor IINon-inhibitor0.9768
Renal organic cation transporterNon-inhibitor0.8975
CYP450 2C9 substrateNon-substrate0.7872
CYP450 2D6 substrateNon-substrate0.9101
CYP450 3A4 substrateNon-substrate0.7282
CYP450 1A2 substrateNon-inhibitor0.8837
CYP450 2C9 inhibitorNon-inhibitor0.5705
CYP450 2D6 inhibitorNon-inhibitor0.9113
CYP450 2C19 inhibitorNon-inhibitor0.8537
CYP450 3A4 inhibitorNon-inhibitor0.9421
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9021
Ames testNon AMES toxic0.9695
CarcinogenicityNon-carcinogens0.8587
BiodegradationReady biodegradable0.8277
Rat acute toxicity2.3552 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.952
hERG inhibition (predictor II)Non-inhibitor0.9555
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral
Tablet325 mg
Tabletoral325 mg
Tablet, film coatedoral580 mg/1
Tabletoral580 mg/1
Tablet, coatedoral
Capsuleoral580 mg/1
Tabletoral650 mg
Tablet, film coatedoral
Prices
Unit descriptionCostUnit
Tricosal 1000 mg tablet1.23USD tablet
Choline mag trisal 1 gm tablet1.15USD tablet
Choline mag trisal 750 mg tablet0.81USD tablet
Novasal 600 mg tablet0.75USD tablet
Choline mag trisal 500 mg tablet0.64USD tablet
Doan's ex strength 580 mg tablet0.22USD tablet
CVS Pharmacy backache rlf 580 mg caplet0.18USD caplet
Doan's regular 325 mg tablet0.18USD tablet
Keygesic-10 650 mg tablet0.05USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0686 mg/mLALOGPS
logP2.86ALOGPS
logP1.98ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)2.79ChemAxon
pKa (Strongest Basic)-6.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area60.36 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity46.13 m3·mol-1ChemAxon
Polarizability12.38 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Satishchandra P. Patel, Vinayak T. Bhalani, “Solid choline magnesium salicylate composition and method of preparing same.” U.S. Patent US5043168, issued May, 1954.

US5043168
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabMagnesium salicylate may increase the anticoagulant activities of Abciximab.
AcebutololMagnesium salicylate may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Aceclofenac.
AcenocoumarolMagnesium salicylate may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Magnesium salicylate.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Magnesium salicylate.
Alendronic acidThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Alendronic acid.
AlfacalcidolThe serum concentration of Magnesium salicylate can be increased when it is combined with Alfacalcidol.
AliskirenMagnesium salicylate may decrease the antihypertensive activities of Aliskiren.
AlprenololMagnesium salicylate may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Magnesium salicylate.
AmikacinMagnesium salicylate may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideMagnesium salicylate may decrease the antihypertensive activities of Amiloride.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Magnesium salicylate.
AmrinoneThe risk or severity of adverse effects can be increased when Amrinone is combined with Magnesium salicylate.
AncrodMagnesium salicylate may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Antipyrine.
Antithrombin III humanMagnesium salicylate may increase the anticoagulant activities of Antithrombin III human.
ApixabanMagnesium salicylate may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Apremilast.
ArdeparinMagnesium salicylate may increase the anticoagulant activities of Ardeparin.
ArgatrobanMagnesium salicylate may increase the anticoagulant activities of Argatroban.
ArotinololMagnesium salicylate may decrease the antihypertensive activities of Arotinolol.
AtenololMagnesium salicylate may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Magnesium salicylate.
AzelnidipineThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Magnesium salicylate.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Magnesium salicylate.
AzimilideThe risk or severity of adverse effects can be increased when Azimilide is combined with Magnesium salicylate.
BalsalazideMagnesium salicylate may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Magnesium salicylate.
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Magnesium salicylate.
BecaplerminMagnesium salicylate may increase the anticoagulant activities of Becaplermin.
BefunololMagnesium salicylate may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Magnesium salicylate.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Magnesium salicylate.
BenidipineThe risk or severity of adverse effects can be increased when Benidipine is combined with Magnesium salicylate.
BenoxaprofenThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Benoxaprofen.
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium salicylate.
BetaxololMagnesium salicylate may decrease the antihypertensive activities of Betaxolol.
BevantololMagnesium salicylate may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Magnesium salicylate.
BisoprololMagnesium salicylate may decrease the antihypertensive activities of Bisoprolol.
BivalirudinMagnesium salicylate may increase the anticoagulant activities of Bivalirudin.
BopindololMagnesium salicylate may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Magnesium salicylate.
BufuralolMagnesium salicylate may decrease the antihypertensive activities of Bufuralol.
BumetanideMagnesium salicylate may decrease the diuretic activities of Bumetanide.
BupranololMagnesium salicylate may decrease the antihypertensive activities of Bupranolol.
CalcitriolThe serum concentration of Magnesium salicylate can be increased when it is combined with Calcitriol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Magnesium salicylate.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Magnesium salicylate.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Magnesium salicylate.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Magnesium salicylate.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Magnesium salicylate.
CarteololMagnesium salicylate may decrease the antihypertensive activities of Carteolol.
CarvedilolMagnesium salicylate may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Magnesium salicylate.
CeliprololMagnesium salicylate may decrease the antihypertensive activities of Celiprolol.
CertoparinMagnesium salicylate may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Magnesium salicylate.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Magnesium salicylate.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Magnesium salicylate.
CholestyramineCholestyramine can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Magnesium salicylate.
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Magnesium salicylate.
CinnarizineThe risk or severity of adverse effects can be increased when Cinnarizine is combined with Magnesium salicylate.
Citric AcidMagnesium salicylate may increase the anticoagulant activities of Citric Acid.
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Magnesium salicylate.
ClodronateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Magnesium salicylate.
ColesevelamColesevelam can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineMagnesium salicylate may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with D-Limonene.
Dabigatran etexilateMagnesium salicylate may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinMagnesium salicylate may increase the anticoagulant activities of Dalteparin.
DanaparoidMagnesium salicylate may increase the anticoagulant activities of Danaparoid.
DarodipineThe risk or severity of adverse effects can be increased when Darodipine is combined with Magnesium salicylate.
DaunorubicinMagnesium salicylate may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Deferasirox.
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Magnesium salicylate.
DesirudinMagnesium salicylate may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Magnesium salicylate.
DextranMagnesium salicylate may increase the anticoagulant activities of Dextran.
Dextran 40Magnesium salicylate may increase the anticoagulant activities of Dextran 40.
Dextran 70Magnesium salicylate may increase the anticoagulant activities of Dextran 70.
Dextran 75Magnesium salicylate may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Magnesium salicylate.
DicoumarolMagnesium salicylate may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Magnesium salicylate.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Magnesium salicylate.
DihydrostreptomycinMagnesium salicylate may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Magnesium salicylate.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Magnesium salicylate.
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Magnesium salicylate.
DotarizineThe risk or severity of adverse effects can be increased when Dotarizine is combined with Magnesium salicylate.
DoxorubicinMagnesium salicylate may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneMagnesium salicylate may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Droxicam.
Edetic AcidMagnesium salicylate may increase the anticoagulant activities of Edetic Acid.
EdoxabanMagnesium salicylate may increase the anticoagulant activities of Edoxaban.
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Magnesium salicylate.
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Magnesium salicylate.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Magnesium salicylate.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Magnesium salicylate.
EnoxaparinMagnesium salicylate may increase the anticoagulant activities of Enoxaparin.
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Magnesium salicylate.
EpirizoleThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Epirizole.
EpirubicinMagnesium salicylate may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneMagnesium salicylate may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Magnesium salicylate.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Magnesium salicylate.
EsmololMagnesium salicylate may decrease the antihypertensive activities of Esmolol.
Etacrynic acidMagnesium salicylate may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Magnesium salicylate.
Ethyl biscoumacetateMagnesium salicylate may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Magnesium salicylate.
EtofenamateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Etoricoxib.
Evening primrose oilThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with exisulind.
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium salicylate.
FenbufenThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fenbufen.
FendilineThe risk or severity of adverse effects can be increased when Fendiline is combined with Magnesium salicylate.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Magnesium salicylate.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Magnesium salicylate.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Magnesium salicylate.
FlunixinThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Magnesium salicylate.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Magnesium salicylate.
Fondaparinux sodiumMagnesium salicylate may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Magnesium salicylate.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Magnesium salicylate.
FramycetinMagnesium salicylate may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideMagnesium salicylate may decrease the diuretic activities of Furosemide.
GabapentinMagnesium salicylate may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Magnesium salicylate.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Magnesium salicylate.
GentamicinMagnesium salicylate may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Haloperidol.
HeparinMagnesium salicylate may increase the anticoagulant activities of Heparin.
HirulogMagnesium salicylate may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with HMPL-004.
HydralazineMagnesium salicylate may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Magnesium salicylate.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Magnesium salicylate.
Hygromycin BMagnesium salicylate may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Magnesium salicylate.
IbuproxamThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Icatibant.
IdarubicinMagnesium salicylate may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Magnesium salicylate.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Magnesium salicylate.
IndenololMagnesium salicylate may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Magnesium salicylate.
IndoprofenThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Magnesium salicylate.
IsoxicamThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Isoxicam.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Magnesium salicylate.
KanamycinMagnesium salicylate may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Magnesium salicylate.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Magnesium salicylate.
LabetalolMagnesium salicylate may decrease the antihypertensive activities of Labetalol.
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Magnesium salicylate.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium salicylate.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Magnesium salicylate.
LepirudinMagnesium salicylate may increase the anticoagulant activities of Lepirudin.
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Magnesium salicylate.
LevobunololMagnesium salicylate may decrease the antihypertensive activities of Levobunolol.
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Magnesium salicylate.
Lipoic AcidMagnesium salicylate can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Magnesium salicylate.
LithiumThe serum concentration of Lithium can be increased when it is combined with Magnesium salicylate.
LornoxicamThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Magnesium salicylate.
LoxoprofenThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Magnesium salicylate.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Magnesium salicylate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Magnesium salicylate.
ManidipineThe risk or severity of adverse effects can be increased when Manidipine is combined with Magnesium salicylate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Magnesium salicylate.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Magnesium salicylate.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Magnesium salicylate.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Magnesium salicylate.
MesalazineMagnesium salicylate may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Magnesium salicylate.
MetamizoleThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Metamizole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Magnesium salicylate.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Magnesium salicylate.
MetipranololMagnesium salicylate may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Magnesium salicylate.
MetoprololMagnesium salicylate may decrease the antihypertensive activities of Metoprolol.
MetrizamideMagnesium salicylate may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MibefradilThe risk or severity of adverse effects can be increased when Mibefradil is combined with Magnesium salicylate.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Magnesium salicylate.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Magnesium salicylate.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Magnesium salicylate.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Magnesium salicylate.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Magnesium salicylate.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Magnesium salicylate.
NadololMagnesium salicylate may decrease the antihypertensive activities of Nadolol.
NadroparinMagnesium salicylate may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Magnesium salicylate.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Magnesium salicylate.
NCX 4016The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with NCX 4016.
NeomycinMagnesium salicylate may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Nepafenac.
NetilmicinMagnesium salicylate may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium salicylate.
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Magnesium salicylate.
Niflumic AcidThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Niflumic Acid.
NiguldipineThe risk or severity of adverse effects can be increased when Niguldipine is combined with Magnesium salicylate.
NiludipineThe risk or severity of adverse effects can be increased when Niludipine is combined with Magnesium salicylate.
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Magnesium salicylate.
NimesulideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Nimesulide.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Magnesium salicylate.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Magnesium salicylate.
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium salicylate.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Magnesium salicylate.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Magnesium salicylate.
OlsalazineMagnesium salicylate may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Magnesium salicylate.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Magnesium salicylate.
OrgoteinThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Orgotein.
OtamixabanMagnesium salicylate may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Magnesium salicylate.
OxprenololMagnesium salicylate may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Oxyphenbutazone.
PamidronateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Parecoxib.
ParomomycinMagnesium salicylate may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololMagnesium salicylate may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateMagnesium salicylate may increase the anticoagulant activities of Pentosan Polysulfate.
PerhexilineThe risk or severity of adverse effects can be increased when Perhexiline is combined with Magnesium salicylate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Magnesium salicylate.
PhenindioneMagnesium salicylate may increase the anticoagulant activities of Phenindione.
PhenprocoumonMagnesium salicylate may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Magnesium salicylate.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Magnesium salicylate.
PinaveriumThe risk or severity of adverse effects can be increased when Pinaverium is combined with Magnesium salicylate.
PindololMagnesium salicylate may decrease the antihypertensive activities of Pindolol.
PiretanideMagnesium salicylate may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Magnesium salicylate.
PlicamycinMagnesium salicylate may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Magnesium salicylate.
PractololMagnesium salicylate may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Magnesium salicylate.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Magnesium salicylate.
PrenylamineThe risk or severity of adverse effects can be increased when Prenylamine is combined with Magnesium salicylate.
ProbenecidThe serum concentration of Magnesium salicylate can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Propacetamol.
PropranololMagnesium salicylate may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Magnesium salicylate.
Protein CMagnesium salicylate may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeMagnesium salicylate may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with PTC299.
PuromycinMagnesium salicylate may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Magnesium salicylate.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Magnesium salicylate.
RaltegravirThe serum concentration of Raltegravir can be decreased when it is combined with Magnesium salicylate.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Magnesium salicylate.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Magnesium salicylate.
ResveratrolThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Resveratrol.
ReviparinMagnesium salicylate may increase the anticoagulant activities of Reviparin.
RibostamycinMagnesium salicylate may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RisedronateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Risedronate.
RivaroxabanMagnesium salicylate may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Magnesium salicylate.
SalicylamideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Magnesium salicylate.
SalsalateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Magnesium salicylate.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Magnesium salicylate.
SeratrodastThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Seratrodast.
SotalolMagnesium salicylate may decrease the antihypertensive activities of Sotalol.
SpectinomycinMagnesium salicylate may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Magnesium salicylate.
SpironolactoneMagnesium salicylate may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with SRT501.
StreptomycinMagnesium salicylate may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinMagnesium salicylate may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfasalazineMagnesium salicylate may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Magnesium salicylate.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Magnesium salicylate.
SulodexideMagnesium salicylate may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Magnesium salicylate.
TacrolimusMagnesium salicylate may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Magnesium salicylate.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Magnesium salicylate.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Magnesium salicylate.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Magnesium salicylate.
TenofovirThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Magnesium salicylate.
TepoxalinThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tiaprofenic acid.
TiludronateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tiludronate.
TimololMagnesium salicylate may decrease the antihypertensive activities of Timolol.
TobramycinMagnesium salicylate may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Magnesium salicylate.
TorasemideMagnesium salicylate may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Magnesium salicylate.
TranilastThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Magnesium salicylate.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Magnesium salicylate.
TriamtereneMagnesium salicylate may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Magnesium salicylate.
TriethylenetetramineThe serum concentration of Magnesium salicylate can be decreased when it is combined with Triethylenetetramine.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Trisalicylate-choline.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Magnesium salicylate.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Magnesium salicylate.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Magnesium salicylate.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium salicylate.
WarfarinMagnesium salicylate may increase the anticoagulant activities of Warfarin.
XimelagatranMagnesium salicylate may increase the anticoagulant activities of Ximelagatran.
XylometazolineThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Magnesium salicylate.
ZaltoprofenThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Zaltoprofen.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Magnesium salicylate.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Magnesium salicylate.
Zoledronic acidThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. [PubMed:15035793 ]
  2. Fiebich BL, Chrubasik S: Effects of an ethanolic salix extract on the release of selected inflammatory mediators in vitro. Phytomedicine. 2004 Feb;11(2-3):135-8. [PubMed:15070163 ]
  3. Chae HJ, Chae SW, Reed JC, Kim HR: Salicylate regulates COX-2 expression through ERK and subsequent NF-kappaB activation in osteoblasts. Immunopharmacol Immunotoxicol. 2004 Feb;26(1):75-91. [PubMed:15106733 ]
  4. Wu KK: Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003 May;3(2):107-12. [PubMed:15199473 ]
  5. Elvira C, Gallardo A, Lacroix N, Schacht E, San Roman J: Incorporation of salicylic acid derivatives to hydrophilic copolymer systems with biomedical applications. J Mater Sci Mater Med. 2001 Jun;12(6):535-42. [PubMed:15348270 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Moon C, Ahn M, Jee Y, Heo S, Kim S, Kim H, Sim KB, Koh CS, Shin YG, Shin T: Sodium salicylate-induced amelioration of experimental autoimmune encephalomyelitis in Lewis rats is associated with the suppression of inducible nitric oxide synthase and cyclooxygenases. Neurosci Lett. 2004 Feb 12;356(2):123-6. [PubMed:14746879 ]
  2. Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. [PubMed:15035793 ]
  3. Sun R, Carlson NG, Hemmert AC, Kishore BK: P2Y2 receptor-mediated release of prostaglandin E2 by IMCD is altered in hydrated and dehydrated rats: relevance to AVP-independent regulation of IMCD function. Am J Physiol Renal Physiol. 2005 Sep;289(3):F585-92. Epub 2005 Apr 19. [PubMed:15840771 ]
  4. Celik G, Pasaoglu G, Bavbek S, Abadoglu O, Dursun B, Mungan D, Misirligil Z: Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma. 2005 Mar;42(2):127-31. [PubMed:15871445 ]
  5. Liu X, Lee TL, Wong PT: Cyclooxygenase-1 inhibition shortens the duration of diazepam-induced loss of righting reflex in mice. Anesth Analg. 2006 Jan;102(1):135-40. [PubMed:16368818 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Zhang Q, Huang Y, Zhao R, Liu G, Chen Y: Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54. doi: 10.1016/j.bios.2008.03.009. Epub 2008 Mar 21. [PubMed:18436441 ]
Comments
comments powered by Disqus
Drug created on July 08, 2007 11:04 / Updated on August 17, 2016 12:23